Clinical Trial Update: A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) [Phase 3]

View source ↗

Summary

Phase 3 trial (PRISM4) of CP101 for prevention of recurrent Clostridioides difficile infection has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• CP101

Snippet

Sponsor: Finch Research and Development LLC. | Conditions: Recurrent C. Difficile Infection | Phase 3 | Status: TERMINATED | Results posted: 2023-11-13